dr reddy?s finds complex generics a good bet

I thought this google alert was worth reading


"Egged on by the US Food and Drugs Administration?s (FDA) approval for its limited-competition generic Arixtra (fondaparinux sodium), Dr Reddy?s Laboratories is altering its generics strategy to focus more on complex molecules for all future launches.

The idea? Gain from minimum competition in the US.

?We will work on more complex molecules and to that effect we may not see a high number of filings (with the FDA) as well. This would also add to the increase in the R&D cost,? GV Prasad, the company?s CEO, said.

Reddy?s is already at an advanced stage of taking yet another complex product ? fexofenadine pseudoephedrine ? and it is expected to be launched sometime during the second quarter of this financial year.

The generic Arixtra, which had a market of about $340 million in 12 months to March, involves about 60 different steps and the process is seen as a major entry barrier for other companies to get approvals before hitting the market."


http://www.dnaindia.com/money/report_fonda-upshot-dr-reddys-finds-complex-generics-a-good-bet_1567777